Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (SANA) is a leading developer of engineered cell therapies targeting complex diseases through innovative gene editing and immune evasion technologies. This resource provides centralized access to official press releases, clinical trial milestones, and strategic updates from the company.
Investors and industry observers will find timely updates on SANA's hypoimmune (HIP) platform progress, allogeneic CAR T-cell therapy developments, and advancements in diabetes/autoimmune disease research. The curated news collection includes regulatory filings, partnership announcements, and financial results essential for tracking this biotechnology innovator.
Key content categories include clinical trial phases, scientific publications, manufacturing expansions, and intellectual property developments. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined monitoring of SANA's progress in creating off-the-shelf cellular medicines. Check back regularly for verified updates on their pipeline targeting oncology, diabetes, and central nervous system disorders.
Sana Biotechnology (NASDAQ: SANA) announced a lease agreement for a new 80,000 sq. ft. manufacturing facility in Bothell, WA, expected to save over $100M in the next three years. This facility will replace the Fremont, CA location and is designed to support multiple product candidates as they approach late-stage clinical development. The company also strengthened its leadership team with the appointments of Snehal Patel as Head of Manufacturing and Julie Lepin as Head of Regulatory Affairs. The move aims to enhance internal manufacturing capabilities without affecting program timelines.
Flagship Pioneering has introduced ProFound Therapeutics, leveraging its ProFoundry™ Platform to discover tens of thousands of novel human proteins, significantly broadening therapeutic targets. The company, founded in 2020, aims to transform human health through unprecedented insights into protein interactions. A commitment of
Sana Biotechnology (NASDAQ: SANA) announced that Terry Fry, M.D., Senior VP and Head of T Cell Therapeutics, will serve as Executive Director at the University of Colorado Gates Institute. Dr. Fry, a leader in CAR T therapies, will maintain his role at Sana while collaborating with academia. The Gates Institute, a $200 million initiative over five years, aims at translating lab findings into cell and gene therapies. The collaboration is expected to enhance Sana's scientific endeavors, reflecting the company's commitment to innovative treatments in gene and cell therapy.
Sana Biotechnology (NASDAQ: SANA) reported its Q1 2022 results, revealing a cash position of $657.4 million as of March 31, down from $746.9 million at the end of 2021. Notable research and development expenses surged to $72.7 million, influenced by increased personnel and manufacturing costs. The net loss narrowed to $31.4 million, or $0.17 per share, compared to $180.6 million in Q1 2021. The company plans to file INDs for its ex vivo and in vivo CAR T programs this year. Additionally, strong conference presentations are scheduled for 2022, highlighting ongoing advancements.
Cellarity has appointed Dr. Sandra Horning to its Board of Directors. Dr. Horning, former Chief Medical Officer at Roche, has extensive experience in drug development, having led the approval of 15 new medicines. Her role is expected to strengthen Cellarity's mission of transforming drug creation through innovative approaches that address complex diseases. The company's unique methodologies utilize high-resolution data and machine learning to enhance drug discovery. This strategic move is viewed positively for future product development.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 3:20 p.m. PT. The presentation will include a business overview by Steve Harr, President and CEO. Investors can access the live webcast on Sana's Investor Relations page, with a replay available for 30 days post-event. Sana focuses on engineered cells as medicines, aiming to repair genes and replace damaged cells, with operations in multiple U.S. locations.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced the acceptance of five abstracts for presentation at the ASGCT 25th Annual Meeting in Washington, D.C. from May 16-19, 2022. The abstracts include two oral presentations on their hypoimmune platform, which aims to enable allogeneic cell transplants without the need for immunosuppression, and two poster presentations on their fusogen platform for targeted gene delivery. The company plans to file two Investigational New Drug applications within the year, focusing on translating their scientific advancements into viable therapeutics.
Tessera Therapeutics has secured over $300 million in Series C financing to advance its GENE WRITING technology aimed at curing genetic diseases. Investors include the Abu Dhabi Investment Authority and Alaska Permanent Fund Corporation. CEO Geoffrey von Maltzahn emphasizes the transformative potential of genetic medicine. The GENE WRITING platform enables precise modifications to DNA, unlocking new treatment possibilities for various conditions. Tessera's innovative approach positions it to potentially lead a new category in genetic medicine.
Sana Biotechnology, Inc. (NASDAQ: SANA) reported a strong cash position of $746.9 million as of December 31, 2021, up from $412.0 million in 2020, driven by a successful IPO. The company is advancing its pipeline, anticipating two IND applications in 2022 for its CAR T programs, SC291 and SG295. Additionally, Sana made significant progress in research and development, including partnerships for stem cells and gene editing. However, the net loss for 2021 was $355.9 million, or $2.14 per share, indicating ongoing financial challenges as they scale operations and clinical trials.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference, scheduled for March 16, 2022, at 6:20 a.m. PT. The event will feature a presentation by CEO Steve Harr, providing a business overview and updates. The webcast can be accessed on the company's Investor Relations page, with a replay available for 30 days post-conference. Sana is focused on developing engineered cell therapies aimed at changing disease treatment.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
